Dosing of Augmentin for Adults with Acute Otitis Media
For adults with acute otitis media, the recommended dosage of Augmentin (amoxicillin/clavulanate) is 875 mg/125 mg twice daily for 5-7 days. 1
Dosing Options Based on Disease Severity
For Mild Disease (No Antibiotics in Previous 4-6 Weeks)
For Moderate Disease or Recent Antibiotic Use
- High-dose amoxicillin/clavulanate (4 g/250 mg per day) 2
- Alternative: Respiratory fluoroquinolones (gatifloxacin, levofloxacin, moxifloxacin) 2
Rationale for Dosing
- Augmentin provides coverage against common otitis media pathogens:
- Streptococcus pneumoniae (including penicillin-intermediate strains)
- Beta-lactamase producing Haemophilus influenzae
- Moraxella catarrhalis 3
- Higher doses are recommended in areas with high prevalence of drug-resistant S. pneumoniae 3
- The addition of clavulanate protects amoxicillin from degradation by beta-lactamase enzymes produced by resistant H. influenzae and M. catarrhalis 3
Treatment Failure Considerations
- If no improvement after 72 hours of therapy:
- For treatment failures, consider:
- Respiratory fluoroquinolones
- Parenteral ceftriaxone (1-2 g/day for 5 days)
- Combination therapy with adequate gram-positive and gram-negative coverage 2
Alternative Options for Penicillin-Allergic Patients
- For non-anaphylactic reactions:
- Cefdinir (300 mg twice daily)
- Cefuroxime (500 mg twice daily)
- Cefpodoxime (200 mg twice daily) 1
- For severe penicillin allergy:
Common Pitfalls and Caveats
Dosing frequency: Twice-daily dosing has shown similar efficacy to three-times-daily dosing with better compliance and potentially fewer gastrointestinal side effects 4
Treatment duration: 5-7 days is typically sufficient for uncomplicated acute otitis media in adults 1
Resistance concerns: Standard-dose amoxicillin may be insufficient in areas with high prevalence of resistant organisms, necessitating higher doses 3
Gastrointestinal side effects: Diarrhea is the most common adverse effect. Consider probiotics to reduce gastrointestinal side effects 1
Monitoring: Reassess after 72 hours if symptoms persist or worsen 2, 1